Alnylam Pharma (ALNY) Tops Q1 EPS by 98c; reiterates guidance

Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($0.16), $0.98 better than the analyst estimate of ($1.14). Revenue for the quarter came in at $494.33 million versus the consensus estimate of $428.05 million.

GUIDANCE:

Alnylam Pharma sees FY2024 revenue of $1.4-1.5 billion, versus the consensus of $1.853 billion.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49